Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
synthetic estrogen
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Ortho_Tri-Cyclen
Yasmin NuvaRing |
| gptkbp:chemicalFormula |
steroid
C20H24O3 |
| gptkbp:composedOf |
acetylation
chemical reaction with estradiol ethinylation |
| gptkbp:contraindication |
liver disease
breast cancer smoking history of thromboembolism |
| gptkbp:drugInterdiction |
estrogenic activity
oral bioavailability 40-60% |
| gptkbp:formulation |
patch
tablet injection vaginal ring |
| gptkbp:gestationPeriod |
Category X
|
| gptkbp:hasFacilities |
296.4 g/mol
|
| https://www.w3.org/2000/01/rdf-schema#label |
ethinyl estradiol acetate
|
| gptkbp:interactsWith |
gptkb:St._John's_Wort
antibiotics anticonvulsants HIV medications |
| gptkbp:isATypeOf |
357-03-3
|
| gptkbp:locatedIn |
1950s
|
| gptkbp:marketedAs |
gptkb:Merck
gptkb:Johnson_&_Johnson gptkb:Pfizer gptkb:Bayer |
| gptkbp:numberOfStudents |
13-27 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
Category X
|
| gptkbp:sideEffect |
headache
nausea breast tenderness mood changes |
| gptkbp:targets |
estrogen_receptors
|
| gptkbp:usedFor |
hormone replacement therapy
contraception |